CTLT Stock Recent News

Catalent's (CTLT) new tie-up to support the development and commercial manufacturing of safe, high-quality AAV gene therapies to provide life-saving treatments to cancer patients.

Catalent (CTLT) reports a solid revenue uptick in third-quarter fiscal 2024 despite lower revenues in Biologics segments.

Catalent (CTLT) came out with a quarterly loss of $0.06 per share versus the Zacks Consensus Estimate of $0.24. This compares to loss of $0.09 per share a year ago.

Investors with an interest in Medical - Drugs stocks have likely encountered both Takeda Pharmaceutical Co. (TAK) and Catalent (CTLT). But which of these two stocks presents investors with the better value opportunity right now?

The parent of Wegovy producer Novo Nordisk has refiled an application to the U.S. Federal Trade Commission (FTC) for approval of a $16.5 billion deal to buy manufacturing subcontractor Catalent , a spokesperson said on Monday.

Novo Holdings CEO Kasim Kutay discusses the surge in income from obesity drug sales and offers an update on the Catalent deal and insight on the company's deal strategy.

Novo Nordisk expects to close its acquisition of Catalent later this year, its chief financial officer said during the company's capital markets day on Thursday, adding that Novo's gross margin is seen falling in the coming years.

Catalent has reduced its headcount by about 300 employees as part of its ongoing restructuring plans, the company disclosed in a regulatory filing on Wednesday.

Catalent (CTLT) reports lower revenues in Biologics segments in its second-quarter fiscal 2024, resulting in overall soft performance.

Although the revenue and EPS for Catalent (CTLT) give a sense of how its business performed in the quarter ended December 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.